+91-8668442535

Anticoagulants Market By Drug Class (Novel Oral Anticoagulants (NOACs), Vitamin K Antagonists, Heparins & Low Molecular Weight Heparins (LMWH), Antiplatelet Agents, Thrombolytic Agents, Direct Thrombin Inhibitors), By Application (Atrial Fibrillation & Heart Attacks, Strokes, Deep Vein Thrombosis (DVT), Pulmonary Embolism) - Growth, Future Prospects, Competitive Analysis, 2018 - 2026

The global anticoagulants market was valued at US$ 33,150.7 million in 2017 and is expected to grow at a compound annual growth rate (CAGR) of 6.6% during the forecast period from 2018 to 2026. Anticoagulants are prescribed to patients who are at higher risk of clot formation in the blood and reduce the risk of serious conditions such as strokes and heart attacks. Anticoagulants are also given to treat pulmonary embolism, deep vein thrombosis (DVT), atrial fibrillation, and other cardiovascular diseases. Thus, the increasing prevalence of cardiovascular diseases, especially DVT, atrial fibrillation, and peripheral artery diseases, is a major growth factor assisting the market. The launch of several novel oral anticoagulants (NOACs) with improved properties in the last decade has completely changed the market scenario over the years. Warfarin, a vitamin K antagonist, was previously the most preferred anticoagulant because it was effective in inhibiting vitamin K recycling. However, the use of warfarin had certain limitations, such as continuous monitoring of the international normalized ratio (INR), i.e., drug levels and drug-food and drug-drug interactions, which acted as drawbacks for the market.

NOACs are also referred to as "non-vitamin K antagonist oral anticoagulants," consisting of coagulation factors Xa inhibitors, factor IIa inhibitors, and direct thrombin inhibitors, which have a faster onset of action and fewer side effects compared to other drugs. The currently marketed NOACs include dabigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Lixiana/Savaysa), and betrixaban (Bevyxxa). Xarelto by Bayer/Janssen Pharmaceuticals and Eliquis by Pfizer/Bristol-Myers Squibb is the most prescribed NOACs globally, owing to their impressive efficacy rates in the trials, lower side-effects such as uncontrollable bleeding, and the ability of the drugs to treat multiple indications, which give them an upper hand in the market. Bevyxxa by Portola Pharmaceuticals was the latest addition to the market, getting U.S. Food and Drug Administration (FDA) approval in June 2017 and launching in January 2018 for the prophylaxis of venous thromboembolism (VTE). This will further drive the market for anticoagulants.

Market Synopsis

Novel Oral Anticoagulants Will Drive the Anticoagulants Market During the Forecast Period

NOACs accounted for more than half of the total anticoagulants market in 2017. The segment is projected to exhibit the fastest growth rate during the forecast period as NOACs provide a higher advantage over vitamin K antagonists in terms of safety, lower side effects such as bleeding episodes, decreased need for continuous dosage monitoring, and availability of anticoagulant reversal agents. Higher prices of NOACs, as compared to other drug segments, also contribute to the growth of the market.

Periods of History and Forecast

This research report presents the analysis of each segment from 2016 to 2026, considering 2017 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments was calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

The anticoagulants market report furnishes quantitative analysis along with its latest market trends. The market is segmented based on drug class, application, and geography.

The market is studied in order to understand the current dynamics and future trends in the global anticoagulants market. The study includes market size and forecasts for all considered segments presented in the report for the period from 2016 to 2026, along with respective compound annual growth rates (CAGRs) for the forecast period from 2018 to 2026, considering 2017 as the base year. The key players currently engaged in the anticoagulants market include Bayer AG, Janssen Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Pfizer, Inc., Daiichi Sankyo Company Limited, and Portola Pharmaceuticals, Inc., among others.

Key questions are answered in this report.

  • How will the global anticoagulants market perform during the forecast period from 2018 to 2026?
  • What are the latest trends in the anticoagulants market and the most valuable opportunities for key players?
  • Who are the leading players in the global anticoagulants market?
  • Which is the leading and fastest-growing region in the global anticoagulants market?
  • What are the drivers and restraints governing the global market for anticoagulants?

Frequently Asked Questions:

The market for Anticoagulants Market is expected to reach US$ 33,150.7 Mn in 2026.

The Anticoagulants Market is expected to see significant CAGR growth over the coming years, at 6.6%.

The report is forecasted to 2018-2026.

The base year of this report is 2017.

Boehringer Ingelheim Internation GmbH,Bayer AG,Johnson & Johnson, Inc.,Bristol-Myers Squibb Company,Pfizer Inc. are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Mar 2019
Category:  Pharmaceuticals
Report ID:   59614
Report Format:   PDF
Pages:   120
Rating:    4.4 (58)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support